The partnership will bring cutting-edge technology to the forefront of research and development
Hyderabad-headquartered GV Research Platform (GVRP) has announced a partnership with Nexel, a leading specialist in induced pluripotent stem cell (iPSC) technology. Through this partnership, GVRP will become Nexel’s authorised distribution partner in India for iPSC-derived cardiomyocytes, hepatocytes, and neurocytes.
This partnership is a significant milestone for the biomedical community in India, as it will bring cutting-edge technology to the forefront of research and development. iPSC-derived cells have the potential to revolutionise drug discovery, toxicity testing, disease modelling, and regenerative medicine. These cells are an essential tool for drug development, as they provide a more physiologically relevant model for testing the efficacy and safety of new compounds.
Dr Choongseong Han, Founder and CEO, Nexel, expressed his pleasure in partnering with GVRP, saying, “The collaboration will expand the reach of our cutting-edge iPSC technology to a wider audience in India. As a world leader in iPSC technology, Nexel has set a new paradigm in the in vitro toxicity field by successfully commercialising iPSC-derived cells that mimic human functionality, making the partnership with GVRP a significant milestone in advancing biomedical research in India.”
Kalyan Korisapati, Co-Founder and CEO of GVRP, said, “We are excited to partner with Nexel to bring their innovative iPSC-derived cells to India. This partnership will allow us to expand our offerings and provide our clients with access to the latest technology in preclinical research. We are confident that this collaboration will have a positive impact on the biomedical community in India and will contribute to advancing the development of new treatments for diseases.”
